Wilson Sonsini Advises NTx on $47.5 Million Series B
Wilson Sonsini Advises NTx on $47.5 Million Series B
Client Highlights11/17/23
Biotech
Our Industry Coverage
Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.
Industry Highlights
Celebrating our founders’ successes
2000
Illumina Completes IPO Worth $96 Million
Diagnostics & Research2009
Genentech Acquired by Roche for $46.8 Billion
Pharmaceuticals2010
Pacific Biosciences Raises $200 Million in IPO
Diagnostics & Research2014
Xenon Pharmaceuticals Launches IPO
Drug Discovery, Pharmaceuticals2016
BioCardia Unveils Reverse Merger
Pharmaceuticals2017
Denali Therapeutics Makes Record BioTech IPO
Drug Discovery2018
WuXi AppTec Raises $356 Million IPO
Diagnostics & Research2018
Allakos Completes IPO Worth $135 Million
Drug Discovery, Pharmaceuticals2019
IGM Biosciences Launches IPO
Biotechnology2020
Applied Molecular Transport Closes IPO at $154 Million
Pharmaceuticals2020
ORIC Pharmaceuticals Raises $138 Million IPO
Pharmaceuticals2020
ALX Oncology Holdings Inc. Closes IPO at $186 Million
Immuno-Oncology2021
Kinnate Biopharma Inc. Raises $276 Million IPO
Drug Discovery, Pharmaceuticals2021
Tenaya Therapeutics Completes IPO Worth $207 Million
Biotechnology2021
Ventyx Biosciences Closes IPO at $175 Million
Biotechnology, Pharmaceuticals2022
Arcellx, Inc. Raises $124 Million IPO
BiotechnologyAttorneys
focused
on this
industry
recent news
we want to share
with you
Wilson Sonsini Advises Aqtual on Series A Funding
Wilson Sonsini Advises Aqtual on Series A Funding
Client Highlights10/31/23
Wilson Sonsini Advises Novo Holdings on MapLight Therapeutics’ $225 Million Series C
Wilson Sonsini Advises Novo Holdings on MapLight Therapeutics’ $225 Million Series C
Client Highlights10/31/23
Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing
Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing
Client Highlights10/25/23